Tonix Pharmaceuticals (TNXP)
(Delayed Data from NSDQ)
$0.18 USD
0.00 (-0.06%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $0.18 0.00 (0.33%) 7:38 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TNXP 0.18 0.00(-0.06%)
Will TNXP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TNXP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TNXP
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Analysts Are Bullish on These Healthcare Stocks: Tonix Pharma (TNXP), OrganiGram Holdings (OGI)
3 Biotech Stocks to Dump Before They Go to Zero
TNXP Stock Earnings: Tonix Pharmaceuticals Beats EPS, Misses Revenue for Q4 2023
Tonix Pharmaceuticals GAAP EPS of -$0.86, revenue of $3.78M